Heat Biologics is having an incredibly strong day in the market today. At the opening bell, the stock was already trading well into the green. From there, we've seen some downward and some upward movement, but it's clear that the stock is staying well away from the red. Below, we'll talk about what we're seeing from HTBX, why, and what we'll be watching for ahead.
What We're Seeing From HTBX
As mentioned above, Heat Biologics is having an incredibly strong day in today's trading session. When the session started for the day, the stock was already trading on impressive gains. While we have seen a bit of downward movement since then, the stock is still holding onto impressive gains and is likely to stay in the green all day. At the moment (10:46), HTBX is trading at $0.99 per share after a gain of $0.03 per share or 4.19% thus far today.
Why The Stock Is Up
As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on HTBX. As soon as we received the alert, the CNA Finance team started working to see exactly what was causing the movement. It didn't take long to dig up the story. The gains are the result of a presentation of clinical data.
Early this morning Heat Biologics announced that it has presented a poster of its immunologic data from its 94 patient Phase 2 trial of HS-410 either alone or in combination with BCG in patients with non-muscle invasive bladder cancer. The presentation was given at the 2017 Genitourinary (GU) Cancers Symposium. For more information with regard to the presentation, click here.
What We'll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on HTBX. In particular, we'll be watching for news with regard to the ongoing work the company is doing on HS-410. Nonetheless, we'll be watching the news closely and bringing it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!